Skip to main content

Advertisement

Table 2 Non-inferiority variables: mixed-effects repeated-measures results, weeks 18 and 26 (per-protocol set)

From: Comparison of two hyaluronic acid formulations for safety and efficacy (CHASE) study in knee osteoarthritis: a multicenter, randomized, double-blind, 26-week non-inferiority trial comparing Durolane to Artz

  Change from baseline Treatment-related
  Artz Durolane difference
(5 × 2.5 ml) (1 × 3 ml, 4 × sham) (Durolane – Artz)
( n= 158) ( n= 161)  
Pain a
Week 18    
 LSM (95% CI) −5.87 (−6.23; −5.52) −5.97 (−6.32; −5.61) −0.09 (−0.58; 0.39)
P value <0.0001 <0.0001 0.7034
Week 26    
 LSM (95% CI) −6.05 (−6.39; −5.71) −6.15 (−6.49; −5.81) −0.10 (−0.56; 0.37)
P value <0.0001 <0.0001 0.6783
Physical function a
Week 18    
 LSM (95% CI) −12.10 (−12.95; −11.26) −12.75 (−13.60; −11.91) −0.65 (−1.81; 0.51)
P value <0.0001 <0.0001 0.2718
Week 26    
 LSM (95% CI) −12.58 (−13.39; −11.77) −13.16 (−13.97; −12.35) −0.58 (−1.69; 0.53)
P value <0.0001 <0.0001 0.3054
Global evaluation b
Week 18    
 LSM (95% CI) 2.55 (2.33; 2.77) 2.70 (2.48; 2.92) 0.15 (−0.15; 0.45)
P value <0.0001 <0.0001 0.3319
Week 26    
 LSM (95% CI) 2.67 (2.45; 2.88) 2.81 (2.59; 3.02) 0.14 (−0.16; 0.43)
P value <0.0001 <0.0001 0.3583
Knee stiffness a
Week 18    
 LSM (95% CI) −1.73 (−1.87; −1.59) −1.87 (−2.00; −1.73) −0.14 (−0.33; 0.05)
P value <0.0001 <0.0001 0.1602
Week 26    
 LSM (95% CI) −1.80 (−1.93; −1.67) −1.95 (−2.08; −1.82) −0.15 (−0.33; 0.03)
P value <0.0001 <0.0001 0.1012
  1. Durolane from Q-med AB (Sweden) and Artz from Seikagaku Corporation (Japan). CI, confidence interval; LSM, ???. aA negative change from baseline is an improvement. bA positive change from baseline is an improvement.